Kiniksa Pharmaceuticals, Ltd. (KNSA) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
Kiniksa Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 3, 2022 7:30 AM EDTARCALYST® (rilonacept) net revenue of $27.0 million in Q2 2022
ARCALYST full-year 2022 net revenue expected to be $115 - $130 million
 Upfront and near-term proceeds of $100 million expected from vixarelimab global license agreement
Cash reserves after the close of the vixarelimab global license agreement expected to fund operations into at least 2025 Conference call and webcast scheduled for 8:30 am ETÂ todayÂ
HAMILTON, Bermuda, Aug. 03, 2022 (GLOBE NEWSWIRE) --... More
